OncoTargets and Therapy (Sep 2019)

Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer

  • Yan W,
  • Hu H,
  • Tang B

Journal volume & issue
Vol. Volume 12
pp. 8015 – 8022

Abstract

Read online

Wenying Yan,1 Hongmei Hu,2 Biao Tang2 1Department of Gynecology, Wangjiang Hospital, Sichuan University, Chengdu, Sichuan Province, People’s Republic of China; 2Department of Gynecology, Sichuan Maternal and Child Health Hospital, Chengdu, Sichuan Province, People’s Republic of ChinaCorrespondence: Biao TangDepartment of Gynecology, Sichuan Maternal and Child Health Hospital, No. 290 Shayan West Second Street, Jinyang Road, Chengdu City, Sichuan Province 610041, People’s Republic of ChinaTel +86 28 8546 3088Email [email protected]: Ovarian cancer, as a common gynecological tumor, is currently recognized as the most lethal gynecological malignancy. In addition to conventional treatment methods such as surgery, radiotherapy and chemotherapy, adoptive immunotherapy represented by modified immune cells also shows good curative effects and is becoming an important method in the treatment of ovarian cancer. Studies have shown that most cancer cells can avoid the recognition of the immune system, thus limiting the anticancer effect of immunotherapy. Chimeric antigen receptor T (CAR-T) cell technology has emerged and has good targeting, killing, proliferation and persistence. A large number of clinical trials also have shown that this technology has achieved great success in improving the quality of life and prolonging the survival time of patients with malignant hematological tumors. CAR-T cell technology has become a research hotspot for immunotherapy. This article mainly reviews various CAR-T cell treatments and their specific mechanisms in the field of ovarian cancer treatment to provide new ideas for the treatment of ovarian cancer.Keywords: immunotherapy, T cell, ovarian cancer, chimeric antigen receptor, tumor antigens

Keywords